1. Home
  2. Companies
  3. AYA
  4. Material Events

Artrya (ASX:AYA) — Material Events

ASX:AYA · 17 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 14 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
14
Artrya Secures A$75M to Accelerate U.S. Rollout of Salix AI PlatformHigh
Artrya raises A$75M placement and launches A$5M SPP to accelerate U.S. expansion of Salix platform
9 Sept 2025 ·Capital Raising ·85
Artrya Advances US Rollout and Nears FDA Submission with $76.6M Cash BackingMedium
Artrya advances US commercial rollout, nears FDA submission for Salix Coronary Flow module, reports $76.6M cash
30 Apr 2026 ·Quarterly Activities & Cashflow Report ·85
Artrya Secures $0.3M U.S. Deal to Expand AI Heart Disease PlatformMedium
Artrya Signs Three-Year US$0.3M Deal with Northeast Georgia Health System for Salix Platform
8 Dec 2025 ·Commercial Agreement Announcement ·85
Artrya Advances with FDA Clearance and U.S. Launch Despite Rising LossesHigh
Artrya reports $16.4M loss, FDA clearance, and U.S. commercial launch of AI coronary artery disease platform
20 Aug 2025 ·Preliminary Final Report ·85
Artrya Advances US Commercialisation with FDA Nod and $80M Capital BoostHigh
Artrya reports $10.7M half-year loss, secures FDA clearance and $80M capital raise to fuel U.S. commercial expansion
25 Feb 2026 ·Appendix 4D Half-year report ·85
Artrya Secures A$60M in First Placement Tranche, SPP Launches TodayMedium
Artrya raises A$60M in first tranche of placement; SPP opens for shareholders
15 Sept 2025 ·Capital Raising ·85
Artrya Secures Five-Year Deal with Cone Health, Boosting U.S. ExpansionMedium
Artrya Secures Third U.S. Customer with Five-Year Cone Health Agreement
23 Dec 2025 ·Commercial Agreement Announcement ·85
Artrya Secures US Customers and Advances FDA Clearance for Salix PlatformMedium
Artrya secures US commercial customers, advances FDA clearance, and completes $80M capital raise
30 Jan 2026 ·Quarterly Activities & Cashflow Report ·85
Artrya Secures $0.6M U.S. Contract as FDA Review AdvancesHigh
Artrya launches Salix platform in U.S., submits FDA plaque module, secures $0.6M Tanner Health contract
28 July 2025 ·Quarterly Activities & Cashflow Report ·85
Artrya Launches Fee-Per-Scan Revenues with Salix Plaque Module at Tanner HealthMedium
Artrya begins fee per scan revenues from Salix Coronary Plaque module with Tanner Health in U.S.
12 Dec 2025 ·Commercial Update ·80
Artrya Secures Ascension for SAPPHIRE Study Expansion in US Cardiac CareMedium
Artrya expands SAPPHIRE Study with Ascension joining as fourth major U.S. healthcare system
13 Nov 2025 ·Clinical Study Expansion Announcement ·75
Artrya Secures Clear FDA Path for Salix Coronary Flow SubmissionMedium
Artrya receives FDA guidance for Salix Coronary Flow 510(k) submission
10 Oct 2025 ·Regulatory Update ·75
Mass General Brigham Joins Artrya’s SAPPHIRE Study to Advance Heart Disease DetectionMedium
Mass General Brigham joins Artrya's SAPPHIRE Study for coronary artery disease detection
5 Nov 2025 ·Clinical Trial Participation Announcement ·75
Artrya Secures $5M in Oversubscribed Share Purchase Plan After $75M PlacementMedium
Artrya completes oversubscribed $5M Share Purchase Plan following $75M placement
3 Oct 2025 ·Capital Raising ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.

Market Mentions 3 - appeared in market wrap coverage

These are market wrap articles where Artrya (ASX:AYA) was mentioned. They reflect broader market coverage, not company-specific announcements.

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Wrap
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026
Wrap
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026
Wrap